The approval will expand lupin’s range of suprax® dosage forms available to treat the approved indications in appropriate patients. suprax ® is currently available?

Suprax® (doxycycline) – Current Availability & Indications

What the New Approval Adds

• Expanded Oral Form: Introduction of a long‑acting, once‑daily oral formulation (e.g., 200 mg once daily) for certain indications such as CAP and certain SSTIs, improving patient adherence.
• Extended‑Release (ER) Option: A new ER tablet allows once‑daily dosing for infections that typically require twice‑daily therapy, potentially reducing side‑effects and simplifying dosing schedules.
• Broader Pediatric Use: A new pediatric suspension (50 mg/5 mL) with a revised dosing algorithm to cover a wider age range (including infants under 6 months) with a clearer weight‑based dosing chart.

Key Points to Remember

1. Dose Adjustments – Dosing may differ by infection site, severity, and patient factors (e.g., renal function, pregnancy).
2. Contraindications – Pregnancy (especially 1st trimester), breastfeeding, and patients with a history of hypersensitivity to doxycycline.
3. Drug Interactions – Avoid concomitant use with antacids, sucralfate, iron or calcium supplements, and certain antibiotics (e.g., fluoroquinolones) that can affect absorption.
4. Side‑Effect Profile – Common: GI upset, photosensitivity, dysgeusia. Rare: esophagitis (if taken improperly), vestibular disturbances with IV dosing.

Bottom Line – Suprax® is already a versatile doxycycline product available as tablets, capsules, oral suspension, and injection. The recent approval broadens the range of dosage forms (especially ER and pediatric formulations) and extends its therapeutic use in key infections, aiming to improve adherence and expand treatment options for appropriate patients. If you have a specific patient scenario or need dosing guidance, feel free to share!